Lincoln Pharma submits SEBI compliance certificate for Q3 FY26
Lincoln Pharmaceuticals Limited submitted a compliance certificate for the quarter ended December 31, 2025. The certificate was issued by the RTA, MUFG Intime India Private Limited, confirming the processing of dematerialised securities.
This is a standard regulatory filing regarding share transfer and dematerialisation, which is a routine operational activity for listed companies and typically has no direct impact on the company's stock or business operations.
The announcement is a routine compliance filing and does not contain any new financial information or business updates that would impact the company's sentiment.
Lincoln Pharmaceuticals Limited has submitted a confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. This certificate was received from M/s. MUFG Intime India Private Limited, the company's Registrar & Share Transfer Agent (RTA).
The RTA confirmed that the securities received from depository participants for dematerialisation during the quarter were processed and listed on the stock exchanges. They also confirmed that the security certificates received were duly verified, cancelled, and that the depositories' names were substituted in the register of members within the stipulated timelines.
The company has requested the stock exchanges to take this submission on record.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.